Evidence map›Paper›PMID 41045303›Full record

ArticleEuropean radiology2026

Preoperative staging of cervical cancer: time to shift from cystoscopy to MRI.

Matteo Bonatti, Riccardo Valletta, Luca D'Erme, Miriam Dolciami, Roberta Chianura, Pietro Paolo Maria Azzaro, Chiara Innocenzi, Nicolò Bizzarri, Vincenzo Vingiani, Giovanni Negri and 7 more

Abstract readMulticenter Study
In one paragraph

Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Matteo BonattiDepartment of Radiology, Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), 5 Böhler Street, 39100, Bolzano, Italy.
Riccardo VallettaDepartment of Radiology, Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), 5 Böhler Street, 39100, Bolzano, Italy.
Luca D'ErmeDepartment of Imaging and Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168, Roma, Italy. luca.derme01@icatt.it.
Miriam DolciamiDepartment of Imaging and Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168, Roma, Italy.
Roberta ChianuraCatholic University of the Sacred Heart, Largo Francesco Vito 1, 00168, Rome, Italy.
Pietro Paolo Maria AzzaroCatholic University of the Sacred Heart, Largo Francesco Vito 1, 00168, Rome, Italy.
Chiara InnocenziCatholic University of the Sacred Heart, Largo Francesco Vito 1, 00168, Rome, Italy.
Nicolò BizzarriDepartment of Women and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Largo Agostino Gemelli 8, 00168, Roma, Italy.
Vincenzo VingianiDepartment of Radiology, Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), 5 Böhler Street, 39100, Bolzano, Italy.
Giovanni NegriDepartment of Pathology, Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), 5 Böhler Street, 39100, Bolzano, Italy.
Martin SteinkassererDepartment of Gynecology and Obstetrics, Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), 5 Böhler Street, 39100, Bolzano, Italy.
Sara NotaroDepartment of Gynecology and Obstetrics, Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), 5 Böhler Street, 39100, Bolzano, Italy.
Francesca VanzoDepartment of Gynecology and Obstetrics, Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), 5 Böhler Street, 39100, Bolzano, Italy.
Elena MagriDepartment of Radiation Oncology, APSS Trento, L.go Medaglie d'Oro 9, 38122, Trento, Italy.
Benedetta GuiDepartment of Imaging and Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168, Roma, Italy.
Evis SalaDepartment of Imaging and Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168, Roma, Italy.
Giacomo AvesaniDepartment of Imaging and Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168, Roma, Italy. giacomo.avesani@policlinicogemelli.it.ORCID http://orcid.org/0000-0001-9926-760X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the impact of MRI-defined bladder wall invasion from uterine cervical cancer (CC) on disease recurrence and overall survival. MATERIALS AND

methodsIRB-approved multicenter retrospective study including women who underwent staging MRI for histologically confirmed CC (Jan 2015-Dec 2020). Image analysis was independently performed by two radiologists. Bladder wall invasion was diagnosed if ≥ 3 of the following criteria were met: loss of the cervix-bladder fat plane, bladder wall thickening, loss of bladder wall T2-hypointensity, and presence of endoluminal tumor growth. MRI findings were compared with endoscopy/cytology. The impact of MRI-defined bladder wall invasion on tumor recurrence and survival was assessed using logistic regression. Survival curves were compared using the log-rank test.

resultsWe included 214 women with a median age of 55 (IQR 47-65) years. MRI-defined bladder wall invasion was observed in 21.5% of patients. Cystoscopy revealed bladder mucosal infiltration in 7.0% of patients, all of whom demonstrated MRI-defined bladder wall invasion. No patients without MRI-defined bladder wall invasion showed mucosal infiltration on cystoscopy/cytology. The median follow-up was 32 months: 46.7% of patients had recurrence, and 23.4% had CC-related death. On logistic regression, MRI-defined bladder wall invasion was an independent risk factor for tumor recurrence (OR 2.24, p = 0.047) and mortality (OR 3.55, p = 0.006), whereas cystoscopy-defined bladder mucosa infiltration was not. The log-rank test demonstrated a significant difference in survival between patients with and without MRI-defined bladder wall invasion (χ² = 15.40, p = 0.0001).

conclusionsMRI-defined bladder wall invasion represents an independent negative prognostic factor in patients with cervical cancer. KEY POINTS: Question The prognostic significance of MRI-defined bladder wall invasion in patients with cervical cancer remains unclear with respect to disease recurrence and survival. Findings Bladder wall invasion identified on MRI is an independent predictor of tumor recurrence and tumor-specific mortality, whereas mucosal infiltration detected via cystoscopy is not. Clinical relevance MRI can safely replace cystoscopy in the preoperative staging of patients with uterine cervical cancer. This approach can reduce costs and expedite the staging process.

Indexed as

CystoscopyMagnetic Resonance ImagingUrinary Bladder NeoplasmsUterine Cervical NeoplasmsAgedFemaleHumansMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPreoperative CareRetrospective StudiesUrinary BladderMagnetic resonance imagingNeoplasm stagingSurvivalUrinary bladderUterine cervical neoplasms

Identifiers

PMID41045303
PMCPMC13035525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.